All In Biotech

Drug Trial Radar · NCT00678327

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma

Last checked: Nov 20, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,202 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,202

Actual

Start

Aug 29, 2008

Primary completion

Jan 31, 2016

Study completion May 1, 2024

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK; Cancer Research UK & UCL Cancer Trials Centre
First posted
May 15, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before, during, and after chemotherapy may help doctors assess a patient's response to treatment and help plan the best treatment. It is not yet known whether FDG-PET/CT imaging is effective in assessing response to chemotherapy in patients with newly diagnosed Hodgkin lymphoma. PURPOSE: This randomized phase III trial is studying FDG-PET/CT imaging to see how well it works in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma.

Conditions

  • Lymphoma

Interventions

  • bleomycin sulfateBiological

    Given IV

  • filgrastimBiological

    Given subcutaneously

  • pegfilgrastimBiological

    Given subcutaneously

  • cyclophosphamideDrug

    Given IV

  • dacarbazineDrug

    Given IV

  • doxorubicin hydrochlorideDrug

    Given IV

  • etoposideDrug

    Given IV

  • prednisoloneDrug

    Given orally

  • procarbazine hydrochlorideDrug

    Given orally

  • vinblastine sulfateDrug

    Given IV

  • vincristine sulfateDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 3-year progression-free survivalTime frame: 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Southampton General Hospital

    Southampton, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.